Afinitor (Everolimus) Patent Expiration, LOE Window & CMS Spending
Afinitor (Everolimus) by Novartis: FDA Orange Book LOE 2028-07-01, 13 AB generics, $53.5M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N022334 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2028-07-01 |
| Orange Book Patents (*PED Extensions) | 3 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 13 |
| 2024 CMS Total Public Spend | $53.5M |
| 2024 Medicare Part D Spend | $17.7M |
| 2024 Medicaid Spend | $35.7M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 18.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.